Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice

被引:10
|
作者
Kroon, Tori [1 ]
Bhadouria, Neharika [2 ]
Niziolek, Paul [3 ]
Edwards, Daniel, III [4 ]
Choi, Roy [5 ]
Clinkenbeard, Erica L. [4 ]
Robling, Alexander [4 ,5 ]
Holguin, Nilsson [4 ,5 ,6 ]
机构
[1] IUPUI, Dept Biomed Engn, Indianapolis, IN USA
[2] Purdue Univ, Dept Mech Engn, W Lafayette, IN 47907 USA
[3] IUPUI, Radiol & Imaging Sci, Indianapolis, IN USA
[4] Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN USA
[5] IUPUI, Dept Anat & Cell Biol, Indianapolis, IN USA
[6] IUPUI, Dept Mech & Energy Engn, Indianapolis, IN USA
关键词
ANABOLIC THERAPEUTICS; CHONDROCYTE AND CARTILAGE BIOLOGY; GENETIC ANIMAL MODELS; PRECLINICAL STUDIES; WNT/beta-CATENIN/LRPs; BONE-FORMATION; NEGATIVE REGULATOR; NOTOCHORDAL CELL; SCLEROSTIN; WNT; ACTIVATION; EXPRESSION; DKK1;
D O I
10.1002/jbmr.4546
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intervertebral disc (IVD) degeneration is a leading cause of low back pain, characterized by accelerated extracellular matrix breakdown and IVD height loss, but there is no approved pharmacological therapeutic. Deletion of Wnt ligand competitor Lrp5 induces IVD degeneration, suggesting that Wnt signaling is essential for IVD homeostasis. Therefore, the IVD may respond to neutralization of Wnt ligand competitors sost(gene)/sclerostin(protein) and/or dickkopf-1 (dkk1). Anti-sclerostin antibody (scl-Ab) is an FDA-approved bone therapeutic that activates Wnt signaling. We aimed to (i) determine if pharmacological neutralization of sclerostin, dkk1, or their combination would stimulate Wnt signaling and augment IVD structure and (ii) determine the prolonged adaptation of the IVD to global, persistent deletion of sost. Nine-week-old C57Bl/6J female mice (n - 6-7/group) were subcutaneously injected 2x/week for 5.5 weeks with scl-Ab (25 mg/kg), dkk1-Ab (25 mg/kg), 3:1 scl-Ab/dkk1-Ab (18.75:6.25 mg/kg), or vehicle (veh). Separately, IVD of sost KO and wild-type (WT) mice (n - 8/group) were harvested at 16 weeks of age. First, compared with vehicle, injection of scl-Ab, dkk1-Ab, and 3:1 scl-Ab/dkk1-Ab similarly increased lumbar IVD height and beta-catenin gene expression. Despite these similarities, only injection of scl-Ab alone strengthened IVD mechanical properties and decreased heat shock protein gene expressions. Genetically and compared with WT, sost KO enlarged IVD height, increased proteoglycan staining, and imbibed IVD hydration. Notably, persistent deletion of sost was compensated by upregulation of dkk1, which consequently reduced the cell nuclear fraction for Wnt signaling co-transcription factor beta-catenin in the IVD. Lastly, RNA-sequencing pathway analysis confirmed the compensatory suppression of Wnt signaling and revealed a reduction of cellular stress-related pathways. Together, suppression of sost/sclerostin or dkk1 each augmented IVD structure by stimulating Wnt signaling, but scl-Ab outperformed dkk1-Ab in strengthening the IVD. Ultimately, postmenopausal women prescribed scl-Ab injections to prevent vertebral fracture may also benefit from a restoration of IVD height and health. (C) 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
引用
收藏
页码:1156 / 1169
页数:14
相关论文
共 50 条
  • [1] Suppression of Sclerostin and Dickkopf-1 levels in patients with fluorine bone injury
    Wang, Wenpeng
    Xu, Jian
    Liu, Kejian
    Liu, Xiaoli
    Li, Changcheng
    Cui, Caiyan
    Zhang, Yuzeng
    Li, Huabing
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2013, 35 (03) : 402 - 407
  • [2] Sclerostin and Dickkopf-1 in Renal Osteodystrophy
    Cejka, Daniel
    Herberth, Johann
    Branscum, Adam J.
    Fardo, David W.
    Monier-Faugere, Marie-Claude
    Diarra, Danielle
    Haas, Martin
    Malluche, Hartmut H.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (04): : 877 - 882
  • [3] Wnt antagonist sclerostin and Dickkopf-1 in gestational diabetes
    Catalano, A.
    Pintaudi, B.
    Morabito, N.
    Giunta, L.
    Loddo, S.
    Corrado, F.
    D' Anna, R.
    Lasco, A.
    Di Benedetto, A.
    DIABETES & METABOLISM, 2017, 43 (04) : 375 - 377
  • [4] SCLEROSTIN AND DICKKOPF-1 IN PREGNANT WOMEN WITH GESTATIONAL DIABETES
    Catalano, A.
    Morabito, N.
    Bellone, F.
    Pintaudi, B.
    Giunta, L.
    Loddo, S.
    Corrado, F.
    D'Anna, R.
    Di Benedetto, A.
    Lasco, A.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S269 - S269
  • [5] Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
    Ke, Hua Zhu
    Richards, William G.
    Li, Xiaodong
    Ominsky, Michael S.
    ENDOCRINE REVIEWS, 2012, 33 (05) : 747 - 783
  • [6] DICKKOPF-1 AND SCLEROSTIN SERUM LEVELS IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS
    Idolazzi, L.
    Rossini, M.
    Viapiana, O.
    Zanotti, R.
    Tripi, G.
    Perbellini, O.
    Risoli, M.
    Bonifacio, M.
    Gatti, D.
    Adami, S.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S248 - S248
  • [7] Dickkopf-1 and Sclerostin Serum Levels in Patients with Systemic Mastocytosis
    Rossini, Maurizio
    Viapiana, Ombretta
    Zanotti, Roberta
    Tripi, Gaia
    Perbellini, Omar
    Idolazzi, Luca
    Bonifacio, Massimiliano
    Adami, Silvano
    Gatti, Davide
    CALCIFIED TISSUE INTERNATIONAL, 2015, 96 (05) : 410 - 416
  • [8] Dickkopf-1 and sclerostin in patients with end stage renal disease
    Cejka, D.
    Diarra, D.
    Foedinger, M.
    Bohle, B.
    Haas, M.
    BONE, 2009, 44 (02) : S275 - S275
  • [9] Dickkopf-1 and Sclerostin Serum Levels in Patients with Systemic Mastocytosis
    Maurizio Rossini
    Ombretta Viapiana
    Roberta Zanotti
    Gaia Tripi
    Omar Perbellini
    Luca Idolazzi
    Massimiliano Bonifacio
    Silvano Adami
    Davide Gatti
    Calcified Tissue International, 2015, 96 : 410 - 416
  • [10] Effect of aromatase inhibitors on learning and memory and modulation of hippocampal dickkopf-1 and sclerostin in female mice
    Saima Zameer
    Divya Vohora
    Pharmacological Reports, 2017, 69 : 1300 - 1307